Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 164

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 164
---
 
   (345,000 
          - 
          - 
  2,904,527 
 (4,531,206 
  8,417,203 
  3,885,997 | ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) |
|:----------------------------------------------------------------------------------------|:----|:------------------|-----------:|:--|:----|:-----|-----------:|:--|
| Interest                                                                                |     | $                 |     79,682 |   |     | $    |    102,373 |   |
| Income taxes                                                                            |     | $                 |          - |   |     | $    |          - |   |
| Supplemental non-cash financing activities:                                             |     |                   |            |   |     |      |            |   |
| Common stock issued for settlement of debt                                              |     | $                 |  1,947,294 |   |     | $    |  2,697,849 |   |
| Warrants issued for financing fees, net of issuance fees of $0 and $8,727, respectively |     | $                 |          - |   |     | $    |     90,816 |   |
| Initial recognition of right of use asset and liability                                 |     | $                 |          - |   |     | $    |    365,556 |   |

<div align='center'>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>

| F-5 |

<div align='center'>Shuttle Pharmaceuticals Holdings, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

September 30, 2024</div>

Note 1 – Organization and Liquidity

Organization and Line of Business

Shuttle Pharmaceuticals Holdings, Inc. (“we,” “us,” “our,” or the “Company”) was originally formed as Shuttle Pharmaceuticals, LLC in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name to Shuttle Pharmaceuticals, Inc. (“Shuttle”). In connection with the conversion the Company issued 5,625,000shares of common stock in exchange for 100% of the outstanding membership interests in Shuttle prior to conversion. On